Tetracyclic DGK Inhibitor Compounds for Cancer Treatment
Summary
USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.
What changed
USPTO granted Patent US12600722B2 to Incyte Corporation covering tetracyclic compounds as DGK (diacylglycerol kinase) inhibitors for therapeutic use, including cancer treatment. The patent contains 63 claims and was applied for on July 17, 2023 under Application No. 18222662.\n\nAffected parties including pharmaceutical companies, drug manufacturers, and clinical researchers should monitor this IP position when developing DGK-targeted therapies or related oncology compounds. The patent grants Incyte exclusive rights to the claimed tetracyclic structures, potentially restricting competing research or commercialization in this therapeutic area.
What to do next
- Monitor for any patent-related proceedings or challenges
- Review product pipeline for potential IP overlap with US12600722B2
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tetracyclic compounds as DGK inhibitors
Grant US12600722B2 Kind: B2 Apr 14, 2026
Assignee
Incyte Corporation
Inventors
Joshua Hummel, Shicheng Shi, Xiaozhao Wang
Abstract
The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
CPC Classifications
C07D 471/22 C07D 498/22 A61P 35/00
Filing Date
2023-07-17
Application No.
18222662
Claims
63
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.